

ASX ANNOUNCEMENT

11 December 2023

Biome signs landmark agreement to develop novel biological Intellectual Property laying the foundations for the next phase of growth

- Biome has executed an agreement with one of its key probiotic research and development partners, to develop multiple novel probiotic strains to be 100% owned by Biome
- Under this agreement development costs are capped at EUR €115,000 per strain
- The agreement includes manufacturing support to ferment the novel strains which Biome intends to commercialise
- Biome is finalising its strategic plan for the next 3 years, known as *Biome Vision 27*, which will be released to market in FY24 and will include IP Development as a key component
- Biome is sufficiently funded for FY24

Microbiome health company **Biome Australia Limited** (ASX: BIO) ('Biome' or 'the company') is pleased to share that it has reached an agreement with one of its key research and development partners to develop multiple novel probiotic strains which Biome expects to result in new intellectual property ownership through future strain bank lodgements and patent applications.

As a key part of Biome's next phase of growth and development, the company is working towards growing its asset base and ownership of key raw materials. These proprietary strains on which the company will base future clinical research will lead to significant additional long term shareholder value generation.

Biome will aim for these new strains to support the development of new products with mainstream gut and immune health targets as well as future therapeutic development for condition-specific live biotherapeutics owned by Biome Australia. These new probiotic strains will "future proof" Biome's Activate Probiotics from competition in the marketplace.

An example of the value of a commercialised probiotic strain is *Lactobacillus rhamnosus* GG, protected under the trademark LGG®. LGG® was acquired by Chr. Hansen in 2016 for EUR €73M (AUD \$120M), including trademarks and related business.¹

Further information on this development program will be shared as part of the *Biome Vision 27* strategic business plan during the second half of FY24. Biome reiterates that the company is sufficiently funded for FY24.

Biome Managing Director, Blair Vega Norfolk said:

"This is a major milestone for Biome on our journey to be a global leader in the probiotic industry. Our goal is to support patients and improve health outcomes with novel, targeted probiotic therapeutics. This agreement which has been several years in the making will provide multiple opportunities to grow our product portfolio with first to market Biome owned products. This is a critical piece in the next phase of Biome's strategic plan, 'Vision 27' that will be released to the market later this financial year.

References:

1. <https://www.marketscreener.com/quote/stock/CHRISTIAN-HANSEN-6275856/news/Chr-Hansen-Holding-A-S-agreed-to-acquire-LGG-business-from-Valio-Ltd-for-73-million-35339790/>

-ENDS-

Approved for release by the Biome Australia board of directors.

About Biome Australia Limited

Biome Australia develops, licenses, commercialises and markets innovative, evidence-based live biotherapeutics (probiotics) and complementary medicines, many of which are supported by clinical research. Biome aims to improve health outcomes and quality of life, and make its products accessible to all.

Incorporated in Australia in 2018, Biome distributes locally and abroad. In partnership with some of the world's leading organisations in microbiome research and development, Biome produced several unique live biotherapeutic (probiotic) products with innovative delivery technologies that improve their stability and efficacy to create its flagship range of complementary medicines: [Activated Probiotics®](#).

Supported by clinical research, including randomised double-blind placebo-controlled trials, Activated Probiotics help prevent and support the management of various health concerns, including low mood and sleep, bone health, iron malabsorption, mild eczema and IBS. Through practitioner-only distribution, Biome is committed to educating health professionals on the newfound systemic health effects of the gut microbiota, helping them to provide innovative, evidence-based natural medicines for the management of some of humanity's most prevalent and chronic health concerns.



Biome Australia

The Microbiome Health Company



q

Biome also develops, licenses and distributes a scientifically formulated, organic nutraceutical range, Activated Nutrients® and a sports performance and recovery range, Activated X Performance®, which is made exclusively for professional athletes.

For more information visit: www.biomeaustralia.com

Investor Relations

Jo Power

corporate@biomeaustralia.com

Media enquiries

media@activated.co

Forward looking statements

*This release may contain forward looking statements, including but not limited to projections, guidance on future revenues, earnings, other potential synergies and estimates and the future performance of Biome (**Forward Looking Statements**).*

Forward Looking Statements are provided as a general guide only and should not be relied upon as an indication or guarantee of future performance. Actual results, performance or achievements may differ materially from those expressed or implied in such Forward Looking Statements and any projections and assumptions on which these Forward Looking Statements are based. Such statements may assume the success of Biome's business strategies. You are cautioned not to place undue reliance on Forward Looking Statements.

The Forward Looking Statements are based on information available to Biome as at the date of this release. Any Forward Looking Statements containing forward looking financial information provided in this release is for illustrative purposes only and is not represented as being indicative of Biome's views on its future financial condition and/or performance. The historic financial information for the September 2021 financial quarter and revenue figures for October and November 2021 have not been audited or reviewed by Biome's auditors. Such information should not be taken as a guide for future performance.

Nothing in this release is a promise or representation as to the future. No representation or warranty, express or implied, is made as to the accuracy, likelihood of achievement or reasonableness of any Forward Looking Statements contained in this release. Except as required by law or regulation (including the ASX Listing Rules), Biome does not undertake to provide any additional or updated information whether as a result of a change in expectations or assumptions, new information, future events or results or otherwise.

To the maximum extent permitted by law, Biome excludes and expressly disclaims all liabilities in respect of, and makes no representation or warranty, express or implied as to the fairness, currency, accuracy, reliability or completeness of information in this release or the accuracy, likelihood of achievement or reasonableness of any Forward Looking Statements (or any event or results expressed or implied in any Forward Looking Statements) contained in, implied by, the information in this release or any part of it, or that this release contains all material information about Biome or which a prospective investor or purchaser may require in evaluating a possible investment in Biome or acquisition of securities in Biome.



Biome Australia Trading Pty Ltd

192-194 Johnston Street, Collingwood, VIC 3066 AUSTRALIA

(03) 9017 5800

support@activated.co

www.biomeaustralia.com

For personal use only



Biome Australia

The Microbiome Health Company



q


Investors are strongly cautioned not to place undue reliance on Forward Looking Statements, particularly in light of the current economic climate and the significant volatility, uncertainty and disruption caused by the Covid-19 pandemic.

For personal use only



Biome Australia Trading Pty Ltd

192-194 Johnston Street, Collingwood, VIC 3066 AUSTRALIA

 (03) 9017 5800

 support@activated.co

 www.biomeaustralia.com